Concepedia

Kevin Ebata

KE

30

Publications

8.8K

Citations

25

H-Index

2003

Active since

Affiliations

Loxo Oncology at Lilly (United States)(Current)

Memorial Sloan Kettering Cancer Center

The University of Texas MD Anderson Cancer Center

Massachusetts General Hospital

Dana-Farber Cancer Institute

Kevin Ebata is an author at Loxo Oncology at Lilly (United States) specializing in medicine, cell biology, and pathology.

ORCID

Top concepts

Publications per year

2003–2023

30

Publications

30

Efficacy of Larotrectinib in <i>TRK</i> Fusion–Positive Cancers in Adults and Children

Alexander Drilon, Theodore W. Laetsch, Shivaani Kummar et al. · New England Journal of Medicine · 2018 · 2.6K citations · Full text

Vitamin C induces Tet-dependent DNA demethylation and a blastocyst-like state in ES cells

Kathryn Blaschke, Kevin Ebata, Mohammad M. Karimi et al. · Nature · 2013 · 868 citations

, , +13

Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer

Alexander Drilon, Geoffrey R. Oxnard, Daniel Shao-Weng Tan et al. · New England Journal of Medicine · 2020 · 810 citations · Full text

Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers

Lori J. Wirth, Eric J. Sherman, Bruce Robinson et al. · New England Journal of Medicine · 2020 · 731 citations · Full text

Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study

Theodore W. Laetsch, Steven G. DuBois, Leo Mascarenhas et al. · The Lancet Oncology · 2018 · 536 citations · Full text

, , +7

Rows per page

1–5 of 30